Exact Mass: 347.1632
Exact Mass Matches: 347.1632
Found 112 metabolites which its exact mass value is equals to given mass value 347.1632,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
AS 1842856
5-Amino-7-(cyclohexylamino)-1-ethyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
5-Amino-1-[(2R,3R,4S,5R)-5-[(benzylamino)methyl]-3,4-dihydroxyoxolan-2-yl]imidazole-4-carboxamide
5-Amino-1-[(2R,3R,4S,5R)-5-[(benzylamino)methyl]-3,4-dihydroxyoxolan-2-yl]imidazole-4-carboxamide
10,20-Dehydro[12,13-dehydroprolyl]-2-(1,1-dimethylallyltryptophyl)diketopiperazine
10,20-Dehydro[12,13-dehydroprolyl]-2-(1,1-dimethylallyltryptophyl)diketopiperazine
delta-(L-alpha-aminoadipoyl)-L-serine-D-valine|delta-(L-alpha-aminoadipyl)-L-seryl-D-valine|L,L,D-alpha-aminodipoyl-serinyl-valine
delta-(L-alpha-aminoadipoyl)-L-serine-D-valine|delta-(L-alpha-aminoadipyl)-L-seryl-D-valine|L,L,D-alpha-aminodipoyl-serinyl-valine
[5-(4-Methylphenyl)-1,2-oxazol-4-yl](4-phenyl-1-piperazinyl)metha none
[5-(4-Methylphenyl)-1,2-oxazol-4-yl](4-phenyl-1-piperazinyl)metha none
Urea, N-cyclopropyl-N-[(1,2-dihydro-6-methyl-2-oxo-3-quinolinyl)methyl]-N-phenyl- (9CI)
Urea, N-cyclopropyl-N-[(1,2-dihydro-6-methyl-2-oxo-3-quinolinyl)methyl]-N-phenyl- (9CI)
(E)-Methyl 3-(2-((tert-butyldimethylsilyloxy)methyl)furo[3,2-b]pyridin-6-yl)acrylate
(E)-Methyl 3-(2-((tert-butyldimethylsilyloxy)methyl)furo[3,2-b]pyridin-6-yl)acrylate
Adiphenine Hydrochloride
Adiphenine Hydrochloride
C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent Adiphenine hydrochloride is a non-competitive inhibitor of nicotinic acetylcholine receptor (nAChR), with an IC50s of 1.9, 1.8, 3.7, and 6.3 μM for α1, α3β4, α4β2, and α4β4, respectively. Adiphenine hydrochloride has anticonvulsant effects[1][2][3].
(2R,4S)-ethyl 5-([1,1-biphenyl]-4-yl)-4-amino-2-methylpentanoate hydrochloride
(2R,4S)-ethyl 5-([1,1-biphenyl]-4-yl)-4-amino-2-methylpentanoate hydrochloride
6-nitro-2-[(4-phenylpiperidin-1-yl)methyl]quinoline
6-nitro-2-[(4-phenylpiperidin-1-yl)methyl]quinoline
N-cyclopropyl-2,6-dimethyl-4-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-3-carboxamide
N-cyclopropyl-2,6-dimethyl-4-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-3-carboxamide
N-(Cyclopropylmethyl)-2-Methyl-5-(5-Methyl-1,3,4-Oxadiazol-2-Yl)biphenyl-4-Carboxamide
N-(Cyclopropylmethyl)-2-Methyl-5-(5-Methyl-1,3,4-Oxadiazol-2-Yl)biphenyl-4-Carboxamide
Leu-Thr-Asp
Leu-Thr-Asp
A tripeptide composed of L-leucine, L-threonine and L-aspartic acid joined in sequence by peptide linkages.
6-(1,3-benzodioxol-5-yl)-N-(cyclopentylmethyl)-4-quinazolinamine
6-(1,3-benzodioxol-5-yl)-N-(cyclopentylmethyl)-4-quinazolinamine
2-hydroxy-2,2-bis(4-methylphenyl)-N-(2-pyridinyl)acetohydrazide
2-hydroxy-2,2-bis(4-methylphenyl)-N-(2-pyridinyl)acetohydrazide
Glu-Ile-Ser
Glu-Ile-Ser
A tripeptide composed of L-glutamic acid, L-isoleucine and L-serine joined by peptide linkages.
3-(1,3-Dihydrobenzimidazol-2-ylidene)-1-pentylquinoline-2,4-dione
3-(1,3-Dihydrobenzimidazol-2-ylidene)-1-pentylquinoline-2,4-dione
7-(diethylamino)-4-(1-methyl-1H-benzimidazol-2-yl)-2H-chromen-2-one
7-(diethylamino)-4-(1-methyl-1H-benzimidazol-2-yl)-2H-chromen-2-one
(2R,3S,4S)-1-[cyclobutyl(oxo)methyl]-4-(hydroxymethyl)-3-[4-(3-pyridinyl)phenyl]-2-azetidinecarbonitrile
(2R,3S,4S)-1-[cyclobutyl(oxo)methyl]-4-(hydroxymethyl)-3-[4-(3-pyridinyl)phenyl]-2-azetidinecarbonitrile
1-[(3aS,4S,9bS)-4-(hydroxymethyl)-8-[2-(3-pyridinyl)ethynyl]-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-c]quinolin-1-yl]ethanone
1-[(3aS,4S,9bS)-4-(hydroxymethyl)-8-[2-(3-pyridinyl)ethynyl]-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-c]quinolin-1-yl]ethanone
1-[(3aR,4R,9bR)-4-(hydroxymethyl)-8-[2-(3-pyridinyl)ethynyl]-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-c]quinolin-1-yl]ethanone
1-[(3aR,4R,9bR)-4-(hydroxymethyl)-8-[2-(3-pyridinyl)ethynyl]-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-c]quinolin-1-yl]ethanone
1-[(3aR,4S,9bR)-4-(hydroxymethyl)-8-[2-(3-pyridinyl)ethynyl]-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-c]quinolin-1-yl]ethanone
1-[(3aR,4S,9bR)-4-(hydroxymethyl)-8-[2-(3-pyridinyl)ethynyl]-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-c]quinolin-1-yl]ethanone
GP531
GP531
GP531 is a potent, second-generation adenosine regulating agent, is pharmacologically silent under basal conditions but increases localized endogenous adenosine during ischemia.
1-hydroxy-3-{[2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl]methylidene}-6h,7h-pyrrolo[1,2-a]pyrazin-4-one
1-hydroxy-3-{[2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl]methylidene}-6h,7h-pyrrolo[1,2-a]pyrazin-4-one
13,14-dimethyl-3,13,17-triazapentacyclo[11.8.0.0²,¹⁰.0⁴,⁹.0¹⁵,²⁰]henicosa-2(10),4,6,8,15,17,19-heptaen-13-ium-19-carboxylate
13,14-dimethyl-3,13,17-triazapentacyclo[11.8.0.0²,¹⁰.0⁴,⁹.0¹⁵,²⁰]henicosa-2(10),4,6,8,15,17,19-heptaen-13-ium-19-carboxylate
(3z)-1-hydroxy-3-{[2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl]methylidene}-6h,7h-pyrrolo[1,2-a]pyrazin-4-one
(3z)-1-hydroxy-3-{[2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl]methylidene}-6h,7h-pyrrolo[1,2-a]pyrazin-4-one
(2s)-2-{[(2s,3r)-2-{[(2s)-2-amino-1-hydroxy-4-methylpentylidene]amino}-1,3-dihydroxybutylidene]amino}butanedioic acid
(2s)-2-{[(2s,3r)-2-{[(2s)-2-amino-1-hydroxy-4-methylpentylidene]amino}-1,3-dihydroxybutylidene]amino}butanedioic acid
(1s,13z)-12,12-dimethyl-10,15,21-triazapentacyclo[13.7.0.0³,¹¹.0⁴,⁹.0¹⁷,²¹]docosa-3(11),4,6,8,13,17-hexaene-16,22-dione
(1s,13z)-12,12-dimethyl-10,15,21-triazapentacyclo[13.7.0.0³,¹¹.0⁴,⁹.0¹⁷,²¹]docosa-3(11),4,6,8,13,17-hexaene-16,22-dione
3-benzyl-5-hydroxy-6-(1h-indol-3-ylmethyl)-1-methyl-3,6-dihydropyrazin-2-one
3-benzyl-5-hydroxy-6-(1h-indol-3-ylmethyl)-1-methyl-3,6-dihydropyrazin-2-one
(3s,6s)-3-benzyl-5-hydroxy-6-(1h-indol-3-ylmethyl)-1-methyl-3,6-dihydropyrazin-2-one
(3s,6s)-3-benzyl-5-hydroxy-6-(1h-indol-3-ylmethyl)-1-methyl-3,6-dihydropyrazin-2-one
12,12-dimethyl-10,15,21-triazapentacyclo[13.7.0.0³,¹¹.0⁴,⁹.0¹⁷,²¹]docosa-3(11),4,6,8,13,17-hexaene-16,22-dione
12,12-dimethyl-10,15,21-triazapentacyclo[13.7.0.0³,¹¹.0⁴,⁹.0¹⁷,²¹]docosa-3(11),4,6,8,13,17-hexaene-16,22-dione
